Announced Wed, 12 Aug · 12:30 IST
Marksans Pharma Q1 FY27 investor presentation posted
Mgmt Guided Margin ImprovementPromoter Disclosed Acquisition PlansOrder Pipeline DisclosedAnalyst Day Multiyear TargetsInvestor Communications View source PDFExplain this filing
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+8.6%1-day move
₹278.95
prior close
₹308.40
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.9-1.0-0.0-0.4+8.6+20.3+18.5+17.0+17.5+15.1————
Up moveDown movePending
AI summary
Marksans Pharma Q1 FY27 revenue rose 35.6% YoY to Rs 841 cr, EBITDA up 112.8% to Rs 213 cr with margin expanding 919 bps to 25.3%, and PAT up 173.9% to Rs 159 cr. UK and Europe surged 74.7% to Rs 356 cr. QliniQ and ABCnow acquisitions completed, cash balance at Rs 1,058 cr, India Ratings outlook revised to Positive.
Likely market impact
Record quarterly EBITDA, sharply expanding margins, and net cash of Rs 1,031 cr position the company for continued inorganic growth across Europe and Canada.